Source:http://linkedlifedata.com/resource/pubmed/id/14639106
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2003-11-25
|
| pubmed:abstractText |
Regarding HER-2/neu expression (gene or protein level) in lung cancer, several studies with inconsistent results have been recently reported, partially due to variable techniques used and/or heterogeneous populations examined. The objective of this study was to examine HER-2/neu expression in a well-defined cohort of non-small-cell lung cancers (NSCLC) and in nonneoplastic lung tissue utilizing a combination of high-density tissue microarray, immunohistochemistry (IHC), and fluorescent in situ hybridization (FISH) under uniform test conditions. One hundred forty stage I-IIIA primary NSCLCs and 38 non-neoplastic lung samples were examined. IHC, using an FDA-approved Hercept monoclonal antibody kit, was performed and HER-2/neu gene alteration was assessed by FISH. The association of expression of HER-2/neu with clinicopathologic parameters was analyzed. Ninety-four percent of tumor samples (131/140) were fully interpretable after tissue processing. Twenty-five of them (19%) overexpressed (2+, 3+) HER-2/neu, while 106 (81%) had no or weak expression. All thirty-four interpretable non-neoplastic lung samples were negative for HER-2/neu alteration at protein and gene level. HER-2/neu protein overexpression correlated well with HER-2/neu gene amplification (r =.83, P < 0.001). HER-2/neu overexpression was significantly associated with histologic subtype: 19 adenocarcinomas (19/82, 23%) versus 4 squamous cell carcinomas (4/44, 9%) overexpressed Her-2/neu (P = 0.04). Statistical significance was observed between HER-2/neu expression and tumor differentiation, with strong positive (3+) expression observed more frequently in poorly differentiated tumors (P = 0.01). Patients with HER-2/neu abnormalities, particularly HER-2/neu gene amplification, exhibited a shorter survival (P = 0.043). The statistically significant difference (P < 0.005) between HER-2/neu alteration in tumor samples(25/131, 19%) and in the nonneoplastic tissue (0/34, 0%) implies that HER-2/neu may have a role in the carcinogenesis of NSCLC. The findings provide evidence supporting the hypothesis that the HER-2/neu receptor may represent a useful molecular target in the treatment of NSCLC. The significant association of HER-2/neu expression and gene amplification with poorly differentiated carcinoma compared with well differentiated carcinoma suggests that HER-2/neu may be involved in NSCLC tumor evolution. Patients with HER-2/neu gene amplification and strong positive expression of HER-2/neu protein showed a strong tendency toward shorter survival.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1052-9551
|
| pubmed:author |
pubmed-author:AndersonTimothyT,
pubmed-author:BeckAmyA,
pubmed-author:DeebGeorgeG,
pubmed-author:LoewenGregoryG,
pubmed-author:NwoguChukwumereC,
pubmed-author:RamnathNithyaN,
pubmed-author:SaitSheilaS,
pubmed-author:SlocumHarry KHK,
pubmed-author:TanDongfengD,
pubmed-author:WangJianminJ,
pubmed-author:WinstonJanetJ,
pubmed-author:WisemanSamS
|
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
201-11
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:14639106-Adult,
pubmed-meshheading:14639106-Aged,
pubmed-meshheading:14639106-Aged, 80 and over,
pubmed-meshheading:14639106-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:14639106-DNA, Neoplasm,
pubmed-meshheading:14639106-Female,
pubmed-meshheading:14639106-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:14639106-Humans,
pubmed-meshheading:14639106-Immunoenzyme Techniques,
pubmed-meshheading:14639106-In Situ Hybridization, Fluorescence,
pubmed-meshheading:14639106-Lung,
pubmed-meshheading:14639106-Lung Neoplasms,
pubmed-meshheading:14639106-Male,
pubmed-meshheading:14639106-Middle Aged,
pubmed-meshheading:14639106-Neoplasm Staging,
pubmed-meshheading:14639106-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:14639106-Proportional Hazards Models,
pubmed-meshheading:14639106-Receptor, erbB-2,
pubmed-meshheading:14639106-Survival Rate
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
|
| pubmed:affiliation |
Department of Pathology, State University of New York, Buffalo, NY 14263, USA. donfeng.tan@roswellpark.org
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|